Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-7479d7b7d-68ccn Total loading time: 0 Render date: 2024-07-12T16:14:50.121Z Has data issue: false hasContentIssue false

Chapter 29 - Management of the gastrointestinal side effects of therapy in older adults with cancer

from Part 4 - Symptom management and supportive care of older adults

Published online by Cambridge University Press:  05 August 2011

By
Laura Raftery ,
Stephen A. Bernard  and
Richard M. Goldberg
Edited by
Arti Hurria  and
Harvey Jay Cohen
Arti Hurria
Affiliation:
City of Hope Cancer Center, California
Harvey Jay Cohen
Affiliation:
Duke University Medical Center, Durham
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Practical Geriatric Oncology , pp. 400 - 418
Publisher: Cambridge University Press
Print publication year: 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Leichman, CG, Fleming, TR, Muggia, FM. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol. 1995;13(6):1303–1311.CrossRefGoogle ScholarPubMed
Rothenberg, ML, Eckardt, JR, Kuhn, JG. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol. 1996;14(4):1128–1135.CrossRefGoogle ScholarPubMed
Sobrero, AF, Aschele, C, Bertino, JR. Fluorouracil in colorectal cancer – a tale of two drugs: implications for biochemical modulation. J Clin Oncol. 1997;15(1):368–381.CrossRefGoogle ScholarPubMed
Mini, E, Trave, F, Rustum, YM. Enhancement of the antitumor effects of 5-fluorouracil by folinic acid. Pharmacol Ther. 1990;47(1):1–19.CrossRefGoogle ScholarPubMed
Petrelli, N, Douglass, Jr HO, Herrera, L. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol. 1989;7(10):1419–26. Erratum, J Clin Oncol 1990;8(1):185.CrossRefGoogle ScholarPubMed
Chiara, S, Nobile, MT, Vincenti, M. Advanced colorectal cancer in the elderly: results of consecutive trials with 5 flourouracil-based chemotherapy. Cancer Chemother Pharmacol. 1998;42:336–340.CrossRefGoogle Scholar
Sargent, D, Goldberg, R, Jacobson, S. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. New Engl J Med. 2001;345:1091–1097.CrossRefGoogle ScholarPubMed
Goldberg, RM, Tabah-Fisch, I, Bleiberg, H. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bi-monthly in elderly patients with colorectal cancer. J Clin Oncol. 2006;24:4085–4091.CrossRefGoogle Scholar
Haller, DG, Catalano, PJ, Macdonald, JS. Phase II study of fluorouracil, leucovorin and lavamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol. 2005;23:8671–8678.CrossRefGoogle Scholar
Folprecht, G, Cunningham, D, Ross, P. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol. 2004;15:1330–1338.CrossRefGoogle ScholarPubMed
Sloan, JA, Goldberg, RM, Sargent, DJ. Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol. 2002;20(6):1491–1498.CrossRefGoogle ScholarPubMed
Balducci, L, Extermann, M. Cancer chemotherapy in the older patient. Cancer. 1997;80(7):1317–1322.3.0.CO;2-A>CrossRefGoogle ScholarPubMed
Bajetta, E, Procopio, G, Celio, L. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol. 2005;23(10):2155–2161.CrossRefGoogle ScholarPubMed
Twelves, C, Wong, A, Nowacki, MP. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352(26):2692–2704.CrossRefGoogle ScholarPubMed
Sharma, R, Rivory, L, Beale, P. A phase II study of fixed dose capecitabine and assessment of predictors of toxicity in patients with advanced metastatic colorectal cancer. Br J Cancer. 2006;94:964–968.CrossRefGoogle ScholarPubMed
Sonis, ST. A biological approach to mucositis. J Support Oncol. 2004;2(1):21–32; discussion 35–36.Google ScholarPubMed
Fuchs, CS, Moore, MR, Harker, G. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol. 2003;21(5):807–814.CrossRefGoogle ScholarPubMed
Sastre, J, Marcuello, E, Masutti, B. Cooperative Group for the Treatment of Digestive Tumors. Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. J Clin Oncol. 2005;23(15):3545–3551.CrossRefGoogle Scholar
Souglakos, J, Pallis, A, Kakolyris, S. Combination of irinotecan plus 5 fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial. Oncology. 2005;69:384–390.CrossRefGoogle ScholarPubMed
Saltz, LB, Cox, JV, Blanke, C. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343:905–914.CrossRefGoogle ScholarPubMed
Rothenberg, ML, Meropol, NJ, Poplin, EA. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol. 2001;19:3801–3807.CrossRefGoogle ScholarPubMed
Porschen, R, Bermann, A, Löffler, T. Fluorouracil plus leucovorin as effective adjuvant chemotherapy in curatively resected stage III colon cancer: results of the trial adjCCA-01. J Clin Oncol. 2001;19:1787–1794.CrossRefGoogle ScholarPubMed
Wolmark, N, Rockette, H, Mamounas, E. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes'; B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol. 1999;17:3553–3559.CrossRefGoogle Scholar
Messersmith, WA, Laheru, DA, Senzer, NN. Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities. Clin Cancer Res. 2004;10(19):6522–6527.CrossRefGoogle ScholarPubMed
Czito, BG, Willett, CG, Bendell, JC. Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. J Clin Oncol. 2006;24(4):656–662.CrossRefGoogle ScholarPubMed
Benson, III AB, Ajani, JA, Catalano, RB. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol. 2004;22(14):2918–2926.CrossRefGoogle ScholarPubMed
Hanani, M, Fellig, Y, Udassin, R. Age-related changes in the morphology of the myenteric plexus of the human colon. Auton Neurosci. 2004;113:71–78.CrossRefGoogle ScholarPubMed
Higgins, PD, Johanson, JF. Epidemiology of constipation in North America: a systemic review. Am J Gastroenterol. 2004;99:750–759.CrossRefGoogle Scholar
Sykes, NP. The relationship between opioid use and laxative use in terminally ill cancer patients. Palliative Med. 1998;12(5):375–382.CrossRefGoogle ScholarPubMed
Luca, A, Coupar, IM. Insights into opioid action in the intestinal tract. Pharmacol Ther. 1996;69(2):103–115.CrossRefGoogle ScholarPubMed
Clark, AJ, Ahmedzai, SH, Allan, LG. Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain. Curr Med Res Opin. 2004;20(9):1419–1428.CrossRefGoogle ScholarPubMed
Staats, PS, Markowitz, J, Schein, J. Incidence of constipation associated with long-acting opioid therapy: a comparative study. South Med J. 2004;97(2):129–134.CrossRefGoogle ScholarPubMed
Plummer, JL, Gourlay, GK, Cherry, DA. Estimation of methadone clearance: applications in the management of cancer pain. Pain 1988;33:313–322.CrossRefGoogle Scholar
Goodman, M, Low, J, Wilkinson, S. Constipation management in palliative care: a survey of practices in the United Kingdom. J Pain Symptom Manage. 2005;29:238–244.CrossRefGoogle ScholarPubMed
,GlaxoSmithKline. Zofran (ondansetron)–package insert. Research Triangle Park, NC; 2009.
Legha, SS. Vincristine neurotoxicity: pathophysiology and management. Med Toxicol. 1986;1:421–427.CrossRefGoogle ScholarPubMed
,Millennium Pharmaceuticals Inc. Velcade (bortezomib) [package insert]. Cambridge, MA; 2007.
,Celgene Corporation. Revlimid (lenalidomide) [package insert]. Summit, NJ; 2007.
,Celgene Corporation. Thalomid (thalidomide) [package insert]. Summit, NJ; 2007.
Richmond, JP, Wright, ME. Review of the literature on constipation to enable development of a constipation risk assessment scale. Clin Eff Nurs. 2004;8:11–25.CrossRefGoogle Scholar
Tuteja, AK, Talley, NJ, Joos, SK. Is constipation associated with decreased physical activity in normally active subjects? Am J Gastroenterol. 2005;100:124–129.CrossRefGoogle ScholarPubMed
Meshkinpour, H, Selod, S, Movahedi, H. Effects of regular exercise in management of chronic idiopathic constipation. Dig Dis Sci. 1998;43(11):2379–2383.CrossRefGoogle ScholarPubMed
Jones, MP, Talley, NJ, Nuyts, G. Lack of objective evidence of efficacy of laxatives in chronic constipation. Dig Dis Sci. 2002;47 2222–2230.CrossRefGoogle ScholarPubMed
,American College of Gastroenterology Chronic Constipation Task Force. An evidence-based approach to the management of chronic constipation in North America. Am J Gastroenterol. 2005;100(suppl 1):S1–S4.CrossRefGoogle Scholar
Ramkumar, D, Rao, SS. Efficacy and safety of traditional medical therapies for chronic constipation: systematic review. Am J Gastroenterol. 2005;100:936–971.CrossRefGoogle ScholarPubMed
Thomas, J, Karver, S, Cooney, GA. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008;358(22):2332–2343.CrossRefGoogle ScholarPubMed
Pollera, CF, Giannarelli, D. Prognostic factors influencing cisplatin-induced emesis: definition and validation of a predictive logistic model. Cancer. 1989;64:1117–1122.3.0.CO;2-R>CrossRefGoogle ScholarPubMed
Roila, F, Tonato, M, Basurto, C. Protection from nausea and vomiting in cisplatin-treated patient: high dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Research. J Clin Oncol. 1989;7:1693–1700.CrossRefGoogle Scholar
D';Acquisto, R, Tyson, LB, Gralla, RJ. The influence of chronic high alcohol intake on chemotherapy induced nausea and vomiting. Proc Am Soc Clin Oncol. 1986;5:257.Google Scholar
Kris, MG, Gralla, RJ, Clark, RA. Incidence, course, and severity of delayed nausea and vomiting following administration of high-dose cisplatin. J Clin Oncol. 1985;3:1379–1384.CrossRefGoogle ScholarPubMed
Miller, AD, Bianchi, AL, Bishop, BP, eds. Neural Control of the Respiratory Muscles. Boca Raton, FL: CRC Press; 1997:239–248.Google Scholar
Andrews, PL, Rudd, JA. Mechanisms of acute, delayed, and anticipatory emesis induced by anticancer therapies. In: Hesketh P, ed. Management of Nausea and Vomiting in Cancer and Cancer Treatment. Boston: Jones and Bartlett; 2005:15–66.Google Scholar
Miller, AD. Central mechanisms of vomiting. Dig Dis Sci. 1999;44(suppl):39S–43S.Google ScholarPubMed
Hornby, PJ.Central neurocircuitry associated with emesis. Am J Med. 2001;111(suppl 8A):106S–112S.CrossRefGoogle ScholarPubMed
Hesketh, P.Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008;358(23): 2482–2494.CrossRefGoogle ScholarPubMed
Olver, IN, Wolf, M, Laidlaw, C. A randomised double-blind study of high-dose intravenous prochlorperazine versus high-dose metoclopramide as antiemetics for cancer chemotherapy. Eur J Cancer. 1992;28A(11):1798–1802.CrossRefGoogle ScholarPubMed
Kris, MG, Tyson, LB, Gralla, RJ. Extrapyramidal reactions with high-dose metoclopramide. N Engl J Med. 1983;309(7):433–434.Google ScholarPubMed
Hickok, JT, Roscoe, JA, Morrow, GR. 5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial. Lancet Oncol. 2005;6:765–772.CrossRefGoogle ScholarPubMed
Aapro, MS, Macciocchi, A, Gridelli, C. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting in elderly patients. J Support Oncol. 2005;5:369–74.Google Scholar
Carpenter, , Briggs, DB, Strominger, N. Responses of neurons of canine area postrema to neurotransmitters and peptides. Cell Mol Neurobiol. 1983;3:113–126.CrossRefGoogle ScholarPubMed
,Emend [package insert], Whitehouse Station (NY): Merck Pharmaceuticals Corp; 2005
Warr, DG, Hesketh, PJ, Gralla, RJ. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 2005;23:2822–2830.CrossRefGoogle ScholarPubMed
Kris, MG, Hesketh, PJ, Somerfield, MR. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol. 2006;24:2932–2947. Erratum, J Clin Oncol. 2006;24:5341–5342.CrossRefGoogle Scholar
Ioannidis, JP, Hesketh, PJ, Lau, J. Contribution of dexamethasone to control of chemotherapyinduced nausea and vomiting: a meta-analysis of randomized evidence. J Clin Oncol. 2000;18:3409–3422.CrossRefGoogle Scholar
Hoffman, HT, Karnell, LH, Funk, GF. The National Cancer Data Base report on cancer of the head and neck. Arch Otolaryngol Head Neck Surg. 1998;124(9):951–962.CrossRefGoogle ScholarPubMed
Bellm, L, Epstein, J, Rose-Ped, A. Patient reports of complications of bone marrow transplantation. Support Care Cancer. 2000;8:33–39.Google ScholarPubMed
Trotti, A, Bellm, L, Epstein, J. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systemic literature review. Radiat Oncol. 203;66:253–262.CrossRef
Elting, L, Cooksley, C, Chambers, M. Risk, outcome, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int J Radiat Oncol Biol Phys. 2007;68:1110–1120.CrossRefGoogle Scholar
Vera-Llonch, M, Oster, G, Hagiwara, M. Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma. Cancer. 2006;106:329–336.CrossRefGoogle ScholarPubMed
Italiano, A, Ortholan, C, Dassonville, O. Head and neck squamous cell carcinoma in patients aged > or = 80 years: patterns of care and survival. Cancer. 2008;113(11):3160–3168.CrossRefGoogle ScholarPubMed
Sonis, ST. The pathobiology of mucositis. Nat Rev Cancer. 2004;4:277–284.CrossRefGoogle ScholarPubMed
Murphy, B. Clinical and economic consequences of mucositis induced by chemotherapy and/or radiation therapy. J Support Oncol. 2007;5: 13–21.Google ScholarPubMed
Cooper, JS, Pajak, TF, Forastiere, AA. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350(19):1937–1944.CrossRefGoogle ScholarPubMed
Shindler, JS, Kelly, JH. Swallowing disorders in the elderly. Laryngoscope. 2002;112(4):589–602.CrossRefGoogle Scholar
Gosselin, TK, Raj, KA, Clough, RW. Amifostine for xerostomia – normal tissue protection at what cost? [abstract]. Int J Radiat Oncol Biol Phys. 2005;63(suppl 1):S128.CrossRefGoogle Scholar
Wasserman, TH, Brizel, DM, Henke, M. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and-neck cancer: 2-year follow-up of a prospective, randomized, phase III trial. Int J Radiat Oncol Biol Phys. 2005;63(4):985–990.CrossRefGoogle ScholarPubMed
Agnosti, JV, Leo-Summers, LS, Inouye, SK. Cognitive and other adverse effects of diphenhydramine use in hospitalized older patients. Arch Intern Med. 2001;161(17):2091–2097.Google Scholar
Brosky, ME. The role of saliva in oral health: strategies for prevention and management of xerostomia. J Support Oncol. 2007;5(5): 215–225.Google ScholarPubMed
Sonis, ST, Oster, G, Fuchs, H. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol. 2001;19(8):2201–2205.CrossRefGoogle ScholarPubMed
Keefe, D, Schubert, M, Etling, L. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer. 2007;109(5):820–831.CrossRefGoogle ScholarPubMed
Zalcberg, J, Kerr, D, Seymour, L. Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Tomudex International Study Group. Eur J Cancer. 1998;34(12):1871–1875.CrossRefGoogle ScholarPubMed
Langer, CJ, Hsu, C, Curran, WJ. Elderly patients with locally advanced non-small cell lung cancer benefit from combined modality therapy: secondary analysis of Radiation Therapy Oncology Group (RTOG) 94–10 [abstract]. Proc Am Soc Clin Oncol. 2002;21:299a.Google Scholar
O';Rourke, IC, Tiver, K, Bull, C. Swallowing performance after radiation therapy for carcinoma of the esophagus. Cancer. 1988;61:2022–2026.3.0.CO;2-0>CrossRefGoogle Scholar
Miller, RC, Martenson, JA, Sargent, DJ. Acute treatment-related diarrhea during postoperative adjuvant therapy for high-risk rectal carcinoma. Int J Radiat Oncol Biol Phys. 1998;41:593–598.CrossRefGoogle ScholarPubMed
Martijn, H, Vulto, JC. Should radiotherapy be avoided or delivered differently in elderly patients with rectal cancer? Eur J Cancer. 2007;43:2301–2306.CrossRefGoogle ScholarPubMed
Cammà, C, Giunta, M, Fiorica, F. Preoperative radiotherapy for resectable rectal cancer: a meta-analysis. J Am Med Assoc. 2000;284(8):1008–1015.CrossRefGoogle ScholarPubMed
Pignon, T, Horiot, JC, Bolla, M. Age is not a limiting factor for radical radiotherapy in pelvic malignancies. Radiother Oncol. 1997;42:107–120.CrossRefGoogle Scholar
Fiorica, F, Cartei, F, Carau, B. Adjuvant radiotherapy on older and oldest elderly rectal cancer patients. Arch Gerontol Geriatr. 2009;49:54–59.CrossRefGoogle ScholarPubMed
Lorchel, F, Peignaux, K, Créhange, G. Preoperative radiotherapy in elderly patients with rectal cancer. Gastroenterol Clin Biol. 2007;31(4):436–441.CrossRefGoogle ScholarPubMed
Athanassiou, H, Antonadou, D, Coliarakis, N. Oncology Hellenic Group. Protective effect of amifostine during fractionated radiotherapy in patients with pelvic carcinomas: results of a randomized trial. Int J Radiat Oncol Biol Phys. 2003;56(4):1154–1160.CrossRefGoogle ScholarPubMed
Kilic, D, Egehan, I, Ozenirler, S. Double-blinded, randomized, placebo-controlled study to evaluate the effectiveness of sulphasalazine in preventing acute gastrointestinal complications due to radiotherapy. Radiother Oncol. 2000;57:125–129.CrossRefGoogle Scholar
Michalski, JM, Winter, K, Purdy, JA. Toxicity after three dimensional radiotherapy for prostate cancer on RTOG 9406 dose level V, Int J Radiat Oncol Biol Phys. 2005;62:706–713.CrossRefGoogle ScholarPubMed
Villaviecencio, RT, Rex, DK, Rahmani, E. Argon plasma coagulation as first line treatment for chronic proctopathy. J Gastroenterol Hepatol. 2004;19(10):1169–1173.Google Scholar
Dall';Era, MA, Hampson, NB, Hsi, RA. Hyperbaric oxygen therapy for radiation induced proctopathy in men treated for prostate cancer. J Urol. 2006;176:87–90.CrossRefGoogle Scholar
Rolston, KV, Bodey, GP, Safdar, A. Polymicrobial infection in patients with cancer: an underappreciated and underreported entity. Clin Infect Dis. 2007;45:228–233.CrossRefGoogle ScholarPubMed
Davila, ML. Neutropenic enterocolitis. Curr Opin Gastroenterol. 2006;22:44–47.Google ScholarPubMed
Schnoll-Sussman, F, Kurtz, RC. Gastrointestinal emergencies in the critically ill cancer patient. Semin Oncol. 2000;27:270–283.Google ScholarPubMed
Przepiorka, D, Anderlini, P, Saliba, R. Chronic graft versus host disease after allogeneic blood stem cell transplantation. Blood. 2001;98:1695–1700.CrossRefGoogle ScholarPubMed
Storb, R, Prentice, RL, Sullivan, KM. Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. Ann Intern Med. 1983;98(4):461–466.CrossRefGoogle ScholarPubMed
McClune, B, Weisdorf, DJ, DiPersio, JF. Non-myeloablative hematopoietic stem cell transplantation in older patients with AML and MDS: results from the Center for International Blood and Marrow Transplant Research (CIBMTR). Blood [abstract]. ASH Annu Meet Abstr. 2008;112:346.Google Scholar
McDonald, GB, Shulman, HM, Sullivan, KM. Intestinal and hepatic complications of human bone marrow transplantation. Part I. Gastroenterology. 1986;90(2):460–477.CrossRefGoogle ScholarPubMed
Herrmann, VM, Petruska, PJ. Nutrition support in bone marrow transplant recipients. Nutr Clin Pract. 1993;8(1):19–27.CrossRefGoogle ScholarPubMed
Mercadante, S. Diarrhea in terminally ill patients: pathophysiology and treatment. J Pain Symptom Manage. 1995;10(4):298–309.CrossRefGoogle ScholarPubMed
McDonald, GB, Shulman, HM, Sullivan, KM. Intestinal and hepatic complications of human bone marrow transplantation. Part I. Gastroenterology. 1986;90(2):460–477.CrossRefGoogle ScholarPubMed
Herrmann, VM, Petruska, PJ. Nutrition support in bone marrow transplant recipients. Nutr Clin Pract. 1993;8(1):19–27.CrossRefGoogle ScholarPubMed
Clark, JW, Eder, JP, Ryan, D. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res. 2005;11(15):5472–5480.CrossRefGoogle ScholarPubMed
Deininger, MW, O'Brien, SG, Ford, JM. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol. 2003;21(8):1637–1647.CrossRefGoogle ScholarPubMed
Moy, B, Goss, PE. Lapatinib-associated toxicity and practical management recommendations. Oncologist. 2007;12(7):756–765.CrossRefGoogle ScholarPubMed
Kane, RC, Bross, PF, Farrell, AT. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist. 2003;8(6):508–513.CrossRefGoogle ScholarPubMed
Accessed 12/04/08: http://www.gene.com/gene/products/information/pdf/tarceva-prescribing.pdf.
Hanna, N, Lilenbaum, R, Ansari, R. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol. 2006;24(33):5253–5258.CrossRefGoogle ScholarPubMed
Cutsem, E, Peeters, M, Siena, S. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007;25(13):1658–1664.CrossRefGoogle ScholarPubMed
Hesketh, PJ, Kris, MG, Grunberg, SM. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol. 1997;15(1):103–109.CrossRefGoogle ScholarPubMed
,World Health Organization. WHO Handbook for Reporting Results: Cancer Treatment. Geneva, Switzerland: World Health Organization, 1979.Google Scholar
Peterson, , Schubert, MM. Oral toxicity. In: The Chemotherapy Source Book. 3rd ed. Baltimore, MD: Williams and Wilkins, 2001.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×